<DOC>
	<DOCNO>NCT00586105</DOCNO>
	<brief_summary>A multicenter uncontrolled study sorafenib patient unresectable and/or metastatic renal cell carcinoma ( RCC ) ass pharmacokinetic profile , safety tolerability , efficacy .</brief_summary>
	<brief_title>Phase III Study Sorafenib Patients With Renal Cell Carcinoma ( RCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients life expectancy least 12 week Patients , suffer unresectable and/or metastatic , measurable RCC histologically cytologically document . Patients rare subtypes RCC pure papillary cell tumor , mixed tumor contain predominantly sarcomatoid cell , Bellini carcinoma , medullary carcinoma , chromophobe oncocytic tumor exclude study participation . Patients receive one prior systemic therapy advance disease complete least 30 day prior first dose study medication . Patients least one unidimensional measurable lesion Computed Tomography ( CT ) scan Magnetic Resonance Imaging ( MRI ) accord Response Evaluation Criteria Solid Tumours ( RECIST ) Patients `` Intermediate '' `` low '' risk per Motzer score Patients Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate bone marrow , liver renal function screen assess follow : Total bilirubin &lt; 1.5 x upper limit normal . Alanine aminotransferase ( ALT ) Aspartate aminotransferase ( AST ) &lt; 2.5 x upper limit normal ( &lt; 5 x upper limit normal patient liver involvement cancer ) . Amylase lipase &lt; 1.5 x upper limit normal . Serum creatinine &lt; 2.0 x upper limit normal . Prothrombin Time ( PT ) International Normalized Ratio ( INR ) Partial Thromboplastin Time ( PTT ) &lt; 1.5 x upper limit normal Previous concurrent cancer distinct primary sit histology cancer evaluate study EXCEPT cervical carcinoma situ , adequately treat basal cell carcinoma , superficial bladder tumor [ Ta ( Noninvasive papillary carcinoma ) , Tis ( Carcinoma situ : `` flat tumor '' ) T1 ( Tumor invade subepithelial connective tissue ) ] cancer curatively treat &gt; 3 year prior study entry ) Patients complete prior systemic treatment regimen less 30 day Cardiac arrhythmia require antiarrhythmic ( exclude beta blocker digoxin ) , symptomatic coronary artery disease ischemia Active clinically serious bacterial fungal infection Known history human immunodeficiency virus ( HIV ) infection chronic hepatitis B C require current interferon treatment Symptomatic metastatic brain meningeal tumor unless patient &gt; 6 month definitive therapy , negative imaging study within 4 week study entry clinically stable respect tumor time study entry . Patients evidence history bleed diathesis . Patients seizure disorder require medication History organ allograft Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result Pregnant breastfeed patient . Excluded concomitant medication : Concurrent anticancer chemotherapy , immunotherapy , hormonal therapy except Bisphosphonates Radiotherapy study within 3 week start study drug . Biological response modifier , GranulocyteColony Stimulating Factor ( GCFS ) Granulocyte macrophage colonystimulating factor ( GMCFS ) , within 3 week prior study entry study Significant surgery within 4 week prior start study drug Autologous bone marrow transplant stem cell rescue within 4 month study Investigational drug therapy within 4 week prior first drug administration study St John 's Wort Xiao Chai Hu Tang Prior concomitant use Bevacizumab , drug ( investigational license ) target Vascular Endothelial Growth Factor ( VEGF ) /VEGFReceptors , Rafkinase inhibitor ( RKI ) , Methyl Ethyl Ketone ( MEK ) Farnesyl transferase inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Sorafenib</keyword>
	<keyword>Nexavar</keyword>
	<keyword>Metastatic RCC</keyword>
	<keyword>Renal Cell Carcinoma</keyword>
	<keyword>Unresectable RCC</keyword>
</DOC>